Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells

• US 7,674,620 B2
• Filed: 03/11/2004
• Issued: 03/09/2010
• Est. Priority Date: 03/12/2003
• Status: Expired due to Fees

• Current Assignee: Reliance Life Sciences Pvt. Ltd.
• Original Assignee: Reliance Life Sciences Pvt. Ltd.
• Inventors: Ravindran, Geeta, Totey, Satish Mahadeorao
• Primary Examiner(s): Romeo; David S
• Assistant Examiner(s): Gamett; Daniel C
• Application Number:
  US10/798,790
• Publication Number:
  US 20060211109A1
• Time in Patent Office: 2,189 Days
• Field of Search: None
• US Class Current: 435/377
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/01 Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/119 Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
• CPC Class Codes: C12N 2501/13 Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2501/41 Hedgehog proteins; Cyclopamine (inhibitor)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0619 Neurons

Abstract

The present disclosure is directed to improved methods for efficiently producing neuroprogenitor cells and differentiated neural cells such as dopaminergic neurons and serotonergic neurons from pluripotent stem cells, for example human embryonic stem cells. Using the disclosed methods, cell populations containing a high proportion of cells positive for tyrosine hydroxylase, a specific marker for dopaminergic neurons, have been isolated. The neuroprogenitor cells and terminally differentiated cells of the present disclosure can be generated in large quantities, and therefore may serve as an excellent source for cell replacement therapy in neurological disorders such as Parkinson'"'"'s disease.

Claims

1. A method of generating a differentiated neural cell population from primate pluripotent stem cells comprising the following steps:

(a) expanding a culture of primate pluripotent stem cells;

(b) culturing the pluripotent stem cells to select for neuroprogenitor cells that are positive for nestin;

(c) sorting the nestin-positive neuroprogenitor cells for enrichment of NCAM-positive cells;

(d) differentiating the nestin-positive, NCAM-positive cells to generate a differentiated neural cell population by culturing the cells in a differentiation media which comprises N-acetyl cysteine and TGF-β

3 or interleukin-1β

or both, wherein the differentiated neural cell population comprises at least about 60% dopaminergic neurons or at least about 30% serotonergic neurons.

2. The method of claim 1, wherein the pluripotent stem cells were derived using a laser ablation technique.

3. The method of claim 1, wherein the pluripotent stem cells are human embryonic stem cells.

4. The method of claim 3, wherein the human embryonic stem cells were derived using a laser ablation technique.

5. The method of claim 1, wherein the differentiated neural cell population comprises at least about 60% dopaminergic neurons and at least about 30% serotonergic neurons.

6. The method of claim 1, further comprising culturing the pluripotent stem cells of step (b) to form embryoid bodies.

7. The method of claim 6, wherein the embryoid bodies are cultured to select for neuroprogenitor cells that are positive for nestin.

8. The method of claim 1, wherein the neuroprogenitor cells that are positive for nestin are selected by culturing the pluripotent stem cells in serum-free medium.

9. The method of claim 8, wherein the serum-free medium is ITSFn serum-free defined medium.

10. The method of claim 8, wherein the serum-free medium comprises one or more soluble factors selected from the group consisting of insulin, sodium selenite, transferrin, and fibronectin.

11. The method of claim 10, wherein the serum-free medium comprises insulin, sodium selenite, transferrin, and fibronectin.

12. The method of claim 7, wherein the neuroprogenitor cells that are positive for nestin are selected by culturing the embryoid bodies in serum-free medium.

13. The method of claim 12, wherein the serum-free medium is ITSFn serum-free defined medium.

14. The method of claim 12, wherein the serum-free medium comprises one or more soluble factors selected from the group consisting of insulin, sodium selenite, basic fibroblast growth factor, transferrin, and fibronectin.

15. The method of claim 14, wherein the serum-free medium comprises insulin, sodium selenite, transferrin, and fibronectin.

16. The method of claim 15, wherein the neuroprogenitor cells comprise at least about 95% nestin-positive cells.

17. The method of claim 1, wherein the nestin-positive neuroprogenitor cells of step (c) are sorted to enrich for NCAM-positive cells by Magnetic Cell Sorting (MACS).

18. The method of claim 17, wherein the nestin-positive neuroprogenitor cells comprise at least about 50-60% NCAM-positive cells.

19. The method of claim 1, further comprising expanding the nestin-positive, NCAM-positive neuroprogenitor cells of step (c) in expansion medium.

20. The method of claim 19, wherein the expansion medium comprises one or more soluble factors selected from the group consisting of insulin, sodium selenite, transferrin, laminin, putrescine, progesterone, basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), sonic hedgehog (SHH), fibroblast growth factor-8 (FGF-8), and brain derived neurotropic factor (BDNF).

21. The method of claim 20, wherein the nestin-positive, NCAM-postive cells are grown in the expansion medium for 6-10 days.

22. The method of claim 20, wherein the nestin-positive, NCAM-postive cells are cultured and serially passed for one or more population doublings.

23. The method of claim 20, wherein the nestin-positive, NCAM-postive cells are cryopreserved in liquid nitrogen.

24. The method of claim 1, wherein the differentiation media comprises Neurobasal medium supplemented with fetal calf serum, B27, ascorbic acid, and N-acetyl cysteine.

25. The method of claim 1, wherein the differentiation media further comprises one or more differentiation agents selected from the group consisting of ascorbic acid, glial cell line derived neurotropic factor (GDNF), dibutyrl-cyclic AMP (db-cAMP), brain derived neurotropic factor (BDNF), neuturin, sonic hedgehog protein (SHH), and fibroblast growth factor-8 (FGF-8).

26. The method of claim 1, wherein the nestin-positive, NCAM-positive cells are grown in differentiation media for 30-50 days.

27. A method of generating dopaminergic neurons from neuroprogenitor cells, comprising enriching the neuroprogenitor cells for cells that are positive for nestin and positive for NCAM, and differentiating the nestin-positive, NCAM-positive cells to generate dopaminergic neurons by culturing the cells in the presence of N-acetyl cysteine and TGF-β

3 or interleukin-1β

or both, wherein at least about 60% of the nestin-positive, NCAM-positive cells differentiate into dopaminergic neurons.

28. A method of generating serotonergic neurons from neuroprogenitor cells, comprising enriching the neuroprogenitor cells for cells that are positive for nestin and NCAM, and differentiating the nestin-positive, NCAM-positive cells to generate serotonergic neurons by culturing the cells in the presence of N-acetyl cysteine and TGF-β

3 or interleukin-1β

or both, wherein at least about 30% of the nestin-positive, NCAM-positive cells differentiate into serotonergic neurons.